¾ÅÉ«

NEW YORK, NY, February 13, 2018 - , a leading provider of services and technologies to support clinical trials and product development for the biopharmaceutical industry, today announced the release of myTI, the company¡¯s ground-breaking mobile application that enables real-time eTMF access and functionality for study teams on the go.

myTI is a mobile extension of Trial Interactive, ¾ÅÉ«¡¯s award-winning cloud-based e-clinical technology designed by clinical professionals for clinical professionals to simplify management of product development, from study start-up to commercialization.  myTI offers significant benefits to Trial Interactive users by placing key eTMF functionality at the fingertips of study teams no matter where they are. By taking these study processes mobile, including secure document capture, query resolution, and task management, myTI enables users to maximize TMF health and keep studies moving at all times.

Highlights of myTI include:

• Document Detection, Capture, and Submission: Securely capture and upload documents using your mobile device camera and a simple auto-capture interface that straightens and adjusts documents prior to PDF conversion and upload.
• Query Resolution: Review documents with queries and resolve them within the mobile interface.
• Document Status: View status, metadata, and update/re-submit expired documents from your phone or tablet.
• Geolocation: Auto-populate site information based on document capture location.
• Role-Specific Access ¨C Customized access levels can be set for CRAs, project managers, TMF leads, and other stakeholders.
• iPhone and iPad iOS: Versions 10.3+ with support back to model 5. Android version to release in Q2 2018.
• Secure Touch ID? and Face ID? Login: Secure and configurable for devices that support TouchID? or Face ID?.
• CFR 21 Part 11 Compliant: Complies with regulatory standards for hosting eTMF documents.

¡°By enabling a move away from archaic paper TMF management, mobile document capture and upload at investigative sites is a huge step forward in product development and for simplifying the significant project management and CRA challenges involved with bringing treatments to market,¡± said Michael Smyth, General Manager of ¾ÅÉ« Life Sciences ¾ÅÉ«. ¡°myTI will equip study teams with on-the-go access to eTMF materials, which will cut lengthy upload timelines and allow filing with near real-time availability, helping to expedite overall timelines and ensuring TMF inspection readiness.¡±

Demos for Trial Interactive myTI can be scheduled by emailing info@trialinteractive.com.

About Trial Interactive
¾ÅÉ«¡¯s Trial Interactive solution provides a collaborative, web-based platform for clinical development that enables sponsors, CROs, IRBs, and other vendors to maintain and update clinical trial documentation in a secure online environment, adhering to global regulatory requirements. With fully searchable solutions including investigator portals, Trial Interactive streamlines study timelines and reduces the administrative burdens of global clinical trials. As part of ¾ÅÉ«¡¯s Life Sciences division, Trial Interactive is dedicated to working with clients on a global, collaborative level, supporting a wide range of requirements including e-feasibility, study start-up, eTMF review/reconciliation, mobile applications, learning management and document management systems, investigator portals, pharmacovigilance and safety management, and endpoint adjudication. For more information on Trial Interactive, please contact info@trialinteractive.com or +1 212.400.8848, or visit www.trialinteractive.com.

About ¾ÅÉ«
is the world¡¯s largest provider of and  for global business. From offices in over 90 cities on six continents, ¾ÅÉ« offers a full range of services in 170+ languages to clients worldwide. More than 4,000 global organizations employ ¾ÅÉ«¡¯s  Product Suite to simplify management of multilingual content. With an unparalleled commitment to quality and client service, ¾ÅÉ« is fully  and  certified. ¾ÅÉ« has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at .